745 related articles for article (PubMed ID: 27913059)
1. CHA
Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus.
Peacock WF; Tamayo S; Sicignano N; Hopf KP; Yuan Z; Patel M
Am J Cardiol; 2017 Mar; 119(5):753-759. PubMed ID: 28081941
[TBL] [Abstract][Full Text] [Related]
3. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
4. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
[TBL] [Abstract][Full Text] [Related]
5. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
Sakuma I; Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
Heart Vessels; 2019 Nov; 34(11):1839-1851. PubMed ID: 31127325
[TBL] [Abstract][Full Text] [Related]
6. Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
Lip GYH; Murphy RR; Sahiar F; Ingall TJ; Dhamane AD; Ferri M; Hlavacek P; Preib MT; Keshishian A; Russ C; Rosenblatt L; Yuce H; Deitelzweig S
JAMA Netw Open; 2022 Aug; 5(8):e2229333. PubMed ID: 36044214
[TBL] [Abstract][Full Text] [Related]
7. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
Coleman CI; Costa OS; Brescia CW; Vardar B; Abdelgawwad K; Sood N
Cardiovasc Diabetol; 2021 Feb; 20(1):52. PubMed ID: 33637082
[TBL] [Abstract][Full Text] [Related]
8. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.
Lip GY; Skjøth F; Rasmussen LH; Larsen TB
J Am Coll Cardiol; 2015 Apr; 65(14):1385-94. PubMed ID: 25770314
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
10. CHA
Kim TH; Yang PS; Kim D; Yu HT; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
Stroke; 2017 Nov; 48(11):2984-2990. PubMed ID: 28939672
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the CHA
Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA
Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry.
Caro Martinez C; Cerezo Manchado JJ; Flores Blanco PJ; Elvira Ruíz G; Albendín Iglesias H; Lova Navarro A; Arregui Montoya F; García Alberola A; Andrés Pascual Figal D; Bailén Lorenzo JL; Navarro-Almenzar B; García-Candel F; Manzano Fernández S
Curr Med Res Opin; 2019 Aug; 35(8):1463-1471. PubMed ID: 30912682
[No Abstract] [Full Text] [Related]
13. CHA
Kim TH; Yang PS; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
Stroke; 2017 Jun; 48(6):1524-1530. PubMed ID: 28455320
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
Lip GY; Lanitis T; Mardekian J; Kongnakorn T; Phatak H; Dorian P
Stroke; 2015 Oct; 46(10):2830-7. PubMed ID: 26316345
[TBL] [Abstract][Full Text] [Related]
15. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Graham DJ; Reichman ME; Wernecke M; Hsueh YH; Izem R; Southworth MR; Wei Y; Liao J; Goulding MR; Mott K; Chillarige Y; MaCurdy TE; Worrall C; Kelman JA
JAMA Intern Med; 2016 Nov; 176(11):1662-1671. PubMed ID: 27695821
[TBL] [Abstract][Full Text] [Related]
16. Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain.
Martí E; Segado A; Pastor-Galán I; Amat P; Remigia MJ; Solano C; Navarro B
Future Cardiol; 2018 May; 14(3s):3-8. PubMed ID: 29848095
[TBL] [Abstract][Full Text] [Related]
17. Clinical profile, management and outcomes in a cohort of elderly and highly comorbid patients with nonvalvular atrial fibrillation treated with rivaroxaban in routine practice.
Brun Guinda D; Callen García Ó; Ondiviela Pérez J; Gracia Aznarez M; Artero Bello P; Rivero Fernandez E; Marquina Barcos A; Villarroel Salcedo M
Future Cardiol; 2018 May; 14(3s):39-45. PubMed ID: 29848090
[TBL] [Abstract][Full Text] [Related]
18. Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed in the last 5 years of use?
Pimentel Quezada Y; Bonilla Palomas JL; Gámez López AL; Moreno Conde M; López Ibáñez MC; Gallego de la Sacristana López-Serrano Á
Future Cardiol; 2018 May; 14(3s):47-53. PubMed ID: 29848089
[TBL] [Abstract][Full Text] [Related]
19. Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain.
Muñiz Lobato S; Tarrazo Tarrazo C; González Fernández E; Morán Alcalá M
Future Cardiol; 2018 May; 14(3s):17-24. PubMed ID: 29848093
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.
Melgaard L; Gorst-Rasmussen A; Lane DA; Rasmussen LH; Larsen TB; Lip GY
JAMA; 2015 Sep; 314(10):1030-8. PubMed ID: 26318604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
